Presented by JJ Eron, Jr, MD, IAS, July 25, 2012. Special Considerations: When and What to Start with Viral Hepatitis Coinfections Joseph J. Eron, Jr,

Slides:



Advertisements
Similar presentations
Single Pill HIV Regimens – Introducing the Quad Pedro Cahn, MD Jean-Pierre Routy, MD Calvin Cohen, MD.
Advertisements

HIV/HCV Coinfection News – HCV Protease Inhibitors
Preparing for Direct Acting Antivirals (DAAs) in PracticeNew Paradigms in the Management of HCV Sherilyn C. Brinkley, MSN, CRNP Nurse Practitioner/Program.
Hepatitis B & Hepatitis C in HIV
Durability of Response and Rate of Re-emergence of Wild Type at Boceprevir (BOC) Resistance-Associated Variant (RAV) Loci in Genotype 1a and 1b Patients:
Douglas T. Dieterich, Juergen K. Rockstroh, Kenneth E. Sherman, Nathalie Adda, Lisa Mahnke, Varun Garg, Shahin Gharakhanian, Scott McCallister, Vincente.
Kidney and bone disease in HIV
Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.
Egyptian Guidelines For Management of Chronic Hepatitis B
Guidelines for Antiviral Treatment of Adults and Adolescents with HIV-1 (including changes, and a little extra on what else is new and current)
Slide #1 Case Study Objectives: Darrel At the conclusion of this case study, learners will be better able to: Predict challenges to HIV care and treatment.
Hepatitis C Treatment in Corrections: New Medicine, New Challenges
Innovative Strategies for the Management of HIV Infection Dual therapies without NRTIs Jean-Guy Baril, MD Clinique médicale du Quartier Latin CHUM This.
Case Study This activity is supported by an educational grant from: Aging Woman with longstanding HIV and multiple comorbidities Dr. Gord Arbess.
Page 1 EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF) TO ABACAVIR (ABC)- BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART), WITH OR WITHOUT.
Case 2: 40-year-old Woman with Long-standing HIV Infection
HBV and HIV HIV and HBV VG Naidoo Gastroenterology.
Optimal therapy in genotype 2 and 3 patients Antonio Craxì Liver & GI Unit, Di.Bi.M.I.S., University of Palermo, Italy
1 Chronic HBV: Current Management Natalie Bzowej, MD, PhD, FRCPC Director Transplant Research Ochsner Medical Center New Orleans, LA.
Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014
IAS–USA Managing Antiretroviral Failure in 2012 Jennifer Hoy, MD Professor of Medicine Director, HIV Medicine The Alfred Hospital FINAL: Presented.
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
IAS–USA Choosing the Initial Antiretroviral Regimen Paul A. Volberding, MD Professor of Medicine University of California San Francisco FINAL:
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.
Hep 202 Just when you thought you knew everything.
Management of HCV in Co-Infected Patients Marie-Louise Vachon, MD, MSc Division of Infectious Diseases Centre Hospitalier Universitaire de Québec.
+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU August 27, 2014.
Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.
How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Prabhdeep Sidhu Candidate PharmD 2015 Western University of Health Sciences Mar 28, 2014.
NYU Medical Grand Rounds Clinical Vignette Alexander Jow, PGY-3 February 21, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
New Treatment Paradigms for Therapeutically-Naïve and Treatment-Experienced HIV Patients A Customized CME Learning Experience.
Gastroenterology and Hepatology Board Review II December 7, 2012.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
IAS–USA Special Considerations: When and What to Start with Viral Hepatitis Coinfections Joseph J. Eron, Jr, MD Professor of Medicine University of North.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU Sept 1, 2015.
Comparison of INSTI vs INSTI  QDMRK  SPRING-2. Eron JJ, Lancet Infect Dis 2011;11: QDMRK  Design  Objective –Non inferiority of RAL QD: % HIV.
SPECIAL CONSIDERATIONS August
Hepatitis C.
Chapter 14: Bloodborne Pathogens. Bloodborne pathogens are transmitted through contact with blood or other bodily fluids Hepatitis, especially hepatitis.
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
Phase 3 Treatment-Naïve and Treatment-Experienced
Drug Induced Liver Disease Tutoring
HIV Part Dos By Alaina Darby.
Phase 3 Treatment-Naïve and Treatment-Experienced
Liver Disease tutoring Part 1
Phase 3 Treatment-Naïve and Treatment-Experienced
Before the start of therapy
Hepatitis Tutoring By Alaina Darby.
EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC ACTG 5202
Phase 3 Treatment-Naïve and Treatment-Experienced
Pharmacokinetics: HIV Drugs
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
Phase 3 Treatment-Naïve and Treatment-Experienced
Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5
Pharmacokinetics: HIV Drugs
Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals  Susanna Naggie, Mark S. Sulkowski  Gastroenterology 
Boceprevir in Treatment Naive SPRINT-2
Phase 3 Treatment Naïve HIV Coinfection
Just when you thought you knew everything.
Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection
Switch to DRV/r monotherapy
Comparison of NNRTI vs PI/r
Phase 3 Treatment-Naïve and Treatment-Experienced
Comparison of NNRTI vs PI/r
Phase 3 Treatment-Naïve and Treatment-Experienced
Presentation transcript:

Presented by JJ Eron, Jr, MD, IAS, July 25, Special Considerations: When and What to Start with Viral Hepatitis Coinfections Joseph J. Eron, Jr, MD Professor of Medicine University of North Carolina at Chapel Hill FINAL: Presented by JJ Eron, Jr, MD, IAS, July 25, 2012.

HCV and HIV – When and What to Start RM is a 62 yo AA MSM who had a h/o injection drug use in 1970’s. He only accepted his sexual orientation in the last 5 years after divorcing his wife. Since that time he has had multiple male sex partners and also consumed more alcohol than his typical 7-10 drinks per week. He has not injected drugs in 40 years. He presents to you after an evening of drinking when he vomited a modest about of blood

Presented by JJ Eron, Jr, MD, IAS, July 25, HCV and HIV – When and What to Start He is found to have HCV genotype 1a and an HCV VL of 2,700,000 c/mL, his HBV surface Ag is negative and surface Ab is positive He is HIV+ with CD4 of 850/µL and VL of 8,000 c/mL On endoscopy he has small varices and no other abnormalities His AST is 90 and ALT 110, INR is 1.4 and albumin is 3.3. Plt count is 110. He has no ascites by exam and RUQ US and his liver is small and nodular appearing His HIV genotype shows K103N

Presented by JJ Eron, Jr, MD, IAS, July 25, What is your next step for his HCV after getting him to stop alcohol intake? 1.Obtain a liver biopsy 2.Obtain a transient elastography 3.Obtain an IL28b genotype 4.None of the above – he needs to be treated no matter what the results are 5.Something else

Presented by JJ Eron, Jr, MD, IAS, July 25, You are confident that he needs HCV treatment but his hepatologist does a biopsy any way. Path is read as F3/4 but when pushed pathologist say more 4 than 3. He has decreased his drinking substantially and is on propranolol. What do you do now? 1.Begin HCV therapy with interferon alfa and ribavirin lead-in and boceprevir 2.Begin HCV therapy with telaprevir, interferon alfa, and ribavirin 3.Begin HIV therapy first 4.Something else

Presented by JJ Eron, Jr, MD, IAS, July 25, You decide that he should begin HIV therapy first and will start HCV therapy once HIV RNA is suppressed. Which NRTI combination will you choose? (HIV RNA 8,000 c/mL, CD4 850/µL and TDR with K103N) 1.TDF/FTC 2.ABC/3TC 3.ZDV/3TC 4.Something else

Presented by JJ Eron, Jr, MD, IAS, July 25, You decide that he should begin HIV therapy first and will start HCV therapy once HIV RNA is suppressed. If you chose TDF/FTC which cART regimen would you start? (HIV RNA 8,000 c/mL, CD4 850/µL and TDR with K103N) 1.FDC TDF/FTC/efavirenz 2.FDC TDF/FTC/ rilpivirine 3.FDC TDF/FTC/cobisistat/elvitegravir 4.FDC TDF/FTC and raltegravir 5.FDC TDF/FTC and atazanavir/r 6.FDC TDF/FTC and darunavir/r 7.Something else

Presented by JJ Eron, Jr, MD, IAS, July 25, You chose TDF/FTC and raltegravir (despite Dr. Eron’s concern re TDR). What HCV therapy will you start when he gets suppressed? 1.Interferon alfa and ribavirin lead-in and boceprevir 2.Telaprevir, interferon alfa, and ribavirin 3.Wait for the next approved drug (12 months or so) 4.Something else

Presented by JJ Eron, Jr, MD, IAS, July 25, HCV and HIV – When and What to Start On HIV therapy HIV RNA falls to < 50 c/mL with 8 weeks and his CD4 increases to 900/µL. However he presents with nausea and vomiting and his AST rises to 459 and ALT to 600, bilirubin rises slightly to 1.2 (was 0.8) and INR = 1.5.

Presented by JJ Eron, Jr, MD, IAS, July 25, What do you do? 1.Freak and call Jurgen Rockstroh 2.Continue treatment with weekly labs 3.Stop HIV therapy and wait for AST/AST to decline and then restart TDF/FTC ATV/r (or similar) 4.Stop HIV therapy and wait for AST/AST to decline and treat his HCV 5.Get a liver biopsy 6.Something else

Slide #11 HIV and HBV Presented by JJ Eron, Jr, MD, IAS, July 25, 2012.

HBV and HIV – What to Start Robin M is Latina and 35 yo who was recently diagnosed with HIV and HBV. She has had one male partner who is also HIV and HBV infected and unfortunately they do not always use condoms. He is currently suppressed on therapy but previously had failed a regimen of ZDV/3TC and EFV in 2005 or 2006 after several years of therapy. Robin M has been avoiding HIV and HBV testing for fear of a positive test. She has obesity (BMI 34), HTN and DM. Her last BP was 138/88 mmHg on lisinopril (ACE) and her last HgbA1C was 6.5% on metformin.

Presented by JJ Eron, Jr, MD, IAS, July 25, HBV and HIV – What to Start Her CD4 cell counts is 358/µL with an HIV RNA of 320,000 c/mL Her HBV viral load is 12,000,000 IU/mL and AST is 58 and ALT 70 IU/mL. INR, albumin and platelets are normal Her eGFR is 40 mL/min and she has 2+ protein and 2+ glc on UA with a urine prot/creatinine ratio of 800

Presented by JJ Eron, Jr, MD, IAS, July 25, A pre-therapy HIV genotype shows M41L and T215D Would you obtain an HBV resistance genotype? 1.Yes 2.No 3.Not sure

Presented by JJ Eron, Jr, MD, IAS, July 25, HBV and HIV – What to Start You decide to get a HBV resistance test even though you are not 100% sure how it will effect your therapy choice. The results show the well-desribed rt M204V/I plus rt L180M mutations associated with lamivudine resistance.

Presented by JJ Eron, Jr, MD, IAS, July 25, Which antiviral combination will you begin? 1.FDC EFV/TDF/FTC 2.TDF/FTC every other day with a recommended third agent 3.TDF/FTC every other day with a recommended third agent plus entecavir 4.ABC/3TC daily with a recommended third agent 5.ABC/3TC daily with a recommended third agent plus entecavir 6.Something else

Presented by JJ Eron, Jr, MD, IAS, July 25, If you chose to add entecavir what dose would you choose? mg daily mg daily 3.No tengo la menor idea!